AOBiome

Executive Summary

AOBiome is a clinical-stage biotechnology company pioneering the development of therapeutics based on its proprietary Ammonia Oxidizing Bacteria (AOB) platform. The company's approach leverages a class-defining, auto-regulating strain of AOB, a human commensal bacterium with well-characterized biochemical properties that are critical for maintaining human health. AOBiome's lead product candidate is being evaluated in Phase 3 clinical trials for inflammatory conditions, with additional programs targeting central nervous system disorders and other diseases. The platform's novel mechanism of action—harnessing the natural immune-modulating effects of AOB—offers potential first-in-class and best-in-class opportunities across multiple therapeutic areas. The company is headquartered in Cambridge, Massachusetts, and has generated significant interest due to its unique approach to the microbiome.

Upcoming Catalysts (preview)

• Q2 2027Phase 3 Top-Line Data Readout for Lead Candidate (B244 in Acne Vulgaris)50% success
• Q4 2026Strategic Partnership or Licensing Deal for AOB Platform40% success
• Q1 2027Series D or Later-Stage Financing Round70% success